Resistance management of temsirolimus

Constitutive activation of the PI3K/AKT/mTOR pathway plays an important role in the pathogenesis of mantle cell lymphoma (MCL), leading to the approval of the mTOR inhibitor Temsirolimus for relapsed or refractory mantle cell lymphoma. However, despite good initial response rates, early relapses were observed during treatment. MET is one of the most upregulated genes in drug-resistant cells and is considered an important proto-oncogene and mediator of drug resistance, but it was not detected in any temsirolimus-sensitive cells.

Pharmacological inhibition of mTOR and Met signaling using a combination of temsirolimus and the RTK inhibitor crizotinib significantly restored sensitivity to temsirolimus. Furthermore, this combination treatment was shown to be synergistic in all MCL cell lines studied and was also active in primary MCL cells. In summary, it was shown for the first time that the overexpression of MET plays an important role in mediating temsirolimus resistance in MCL, and that the combined treatment of temsirolimus and crizotinib is a very promising treatment for MCL and an effective strategy to overcome temsirolimus resistance. However, since everyone’s physique is different and their resistance to drugs is also different, if you experience discomfort after using the drug, please inform your doctor in time.

The original drug temsirolimus has not yet been marketed in China, and therefore cannot be included in domestic medical insurance. The original temsirolimus drug marketed overseas has a Turkish version and a European version. The ingredients of the two are basically the same. The price of each box of 30mg/1.2mL may be more than 10,000 yuan, and the price of 25mg/mL may be around 3,000 yuan per box (the price may fluctuate due to exchange rates). There is currently no generic version of temsirolimus available on the market. For more drug information and specific prices, please consult a medical consultant.